Back to results

MP1032 Treatment in Patients With Moderate to Severe COVID-19

Primary Purpose

COVID-19

Status

Completed

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

MP1032

Placebo

About this trial

This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, MP1032

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

Participant is admitted to hospital and has a positive severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) test by standard reverse transcription-polymerase chain reaction (RT-PCR) assay or equivalent test
Participant has the presence of any symptom(s) suggestive of moderate or severe systemic illness with COVID-19

Key Exclusion Criteria:

Participant, in opinion of the investigator, is not likely to survive >=48 hours beyond Day 1
Participant has a diagnosis of asymptomatic COVID-19, mild COVID-19, or critical COVID-19 on Day 1
Participant has a documented medical history of infection with hepatitis A, B, C, or with human immunodeficiency virus (with a detectable viral load and CD4 count <500 cells per micro liter), or a documented active infection with tuberculosis.
The Participant has clinically significant electrocardiogram (ECG) abnormalities at screening

Other protocol defined inclusion/exclusion criteria may apply

Sites / Locations

Snake River Research PLLC
Richmond University Medical Center
MHAT Blagoevgrad AD
MHAT Sv. Ivan Rilski Kozloduy
MHAT Dr. Stamen Iliev AD
SHATPD Pernik EOOD
MHAT Dr. Ivan Seliminski AD
Umhatem"N.I.Pirogov"
SHATPPD Sata Zagora EOOD
Centre Hospitalier Victor Dupouy
CHU de Grenoble Alpes
Centre Hospitalier Lyon Sud
DE KK Infektológiai Klinika
Flor Ferenc Hospital of Pest County
Ospedale GB Morgagni
Ospedale SM Goretti
IRCCS Ospedale San Raffaele
ASST-FBF-SACCO - Ospedale Luigi Sacco
Policlinico di Napoli
Ospedale "Santo Spirito! Pescara
Policlinico Agostino Gemelli
Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes"
Spitalul Municipal Caracal
Spitalul Clinic de Boli Infectioase "Sfanta Parascheva"
Clinica Anestezie si Terapie Intensiva
Hospital Clinic de Barcelona Hospital Clinic i Provincial
Hospital Ramon y Cajal, Edificio Central
Hospital Clínico Universitario de Salamanca
Hospital Universitario Marqués de Valdecilla/IDIVAL
Hospital Universitario de Valme
Hospital Álvaro Cunqueiro

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

MP1032

Placebo

Arm Description

Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.

Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.

Outcomes

Primary Outcome Measures

Percentage of Participants With Disease Progression Using National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale at Day 14

Disease progression was defined as the percentage of participants who were not alive or who had respiratory failure. Respiratory failure was defined as participants who had a score of 2, 3 or 4 on the NIAID 8-point ordinal scale: The NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status.

Secondary Outcome Measures

Percentage of Participants With Disease Progression Using NIAID 8-point Ordinal Scale at Day 28

Disease progression was defined as the percentage of participants who were not alive or who had respiratory failure. Respiratory failure was defined as participants who had a score of 2, 3 or 4 on the NIAID 8-point ordinal scale: The NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or ECMO; 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status.

Percentage of Participants With Disease Resolution at Day 28

Disease resolution was defined as participants who were alive and had a score of 6, 7, or 8 on the NIAID 8-point ordinal scale. The NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or ECMO; 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status.

All-cause Mortality Rate up to Day 28

All-cause mortality rate was the percentage of participants in each treatment group who died by Day 28 were reported.

Change From Baseline in Clinical Status Score Related to COVID-19 According to the NIAID 8-point Ordinal Scale at Day 28

The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale was defined as follows: 1=Death, 2=Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO), 3=Hospitalized, on non-invasive ventilation or high-flow oxygen devices, 4=Hospitalized, requiring supplemental oxygen, 5=Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise), 6=Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons), 7=Not hospitalized, limitation on activities, and/or requiring home oxygen, 8=Not hospitalized, no limitations on activities. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status.

Percentage of Participants With Disease Resolution at Day 14

All-cause Mortality Rate up to Day 14 and Day 60

The percentage of participants who died by Day 14 and Day 60 were reported.

Change From Baseline in Clinical Status Score Related to COVID-19 According to the NIAID 8-point Ordinal Scale at Day 14

The NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or ECMO; 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status. The change from baseline in NIAID clinical status score related to COVID-19 at Day 14 were reported.

Percentage of Participants Who Required Invasive Ventilation (Mechanical Ventilator and/ ECMO), or Who Died at Day 14 and Day 28

Percentage of participants who required invasive mechanical ventilation/ECMO or who died by Day 14 and Day 28 were reported.

Change From Baseline in Clinical Status Score of the NIAID 8-point Ordinal Scale at Each Visit

Time to (First) Improvement of at Least 1 Category on the NIAID 8-point Ordinal Scale

The NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or ECMO; 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Participants who did not improve at least 1 category on the NIAID scale or died before Day 28 were censored at Day 28. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status.

Percentage of Participants With Clinical Status Improvement of at Least 1 Category From Baseline on the NIAID 8-point Ordinal Scale at Day 14 and Day 28

NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or ECMO; 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Higher score = improvement in clinical status. Percentage of Participants with Clinical Status Improvement of at least 1 category from baseline on the NIAID 8-point Ordinal Scale at Day 14 and Day 28 were reported.

Time to Discharge by Day 28 and Day 60

Time to discharge i.e., the total duration of participant hospitalization from baseline to discharge at Day 28 and Day 60 was reported.

Percentage of Participants Who Were Alive and Tested Negative for COVID-19 at Day 14, Day 28, and Day 60

Percentage of participants who were alive and tested negative for COVID-19 at Day 14, Day 28, and Day 60 were reported.

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An Adverse Event (AE) was any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at screening, worsens during the study, regardless of the suspected cause of the event. TEAE was defined as any adverse event which starts or worsens at any time after initiation of study drug until the end of the follow-up period at Day 60. An SAE was any untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Number of participants with TEAEs and Serious TEAEs were reported.

Number of Participants With Clinically Significant Change in Vital Sign

Vital sign parameters included of systolic and diastolic blood pressure, heart rate, respiration rate, oxygen saturation (SpO2), and body temperature. Any clinically significant change in vital signs were judged by the investigator. Number of participants with clinically significant change in vital sign values were reported.

Number of Participants With Clinically Significant Abnormalities in Physical Examinations

Physical examination included examination of respiratory, cardiovascular, dermatological, neurological, and gastrointestinal system. Any clinically significant abnormalities in physical examination were judged by the investigator. Number of participants with clinically significant abnormalities in physical examinations findings were reported.

Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Results

Clinical laboratory tests included biochemistry, hematology and urinalysis. Any clinically significant abnormalities in clinical laboratory results were judged by the investigator. Number of participants with clinically significant abnormalities in laboratory results were reported.

Maximum Observed Plasma Concentration (Cmax) of MP1032

Cmax of MP1032 in plasma were reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.

Area Under the Plasma Concentration-time Curve From Time Zero to Last Non-zero Concentration (AUC0-t) of MP1032

AUC0-t of MP1032 in plasma were reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.

Apparent Elimination Rate Constant (Kel) of MP1032

Kel was calculated using negative of the estimated slope of the linear regression of the ln-transformed plasma concentration versus time profile in the terminal elimination phase. Kel of MP1032 in plasma were reported.

Apparent Body Clearance (CL/F) of MP1032

Cl/F was estimated as Dose/AUC0-inf. CL/F of MP1032 in plasma was reported.

Apparent Volume of Distribution (Vz/F) of MP1032

Vz/F was estimated as Dose/(Kel x AUC0-inf). Vz/F of MP1032 in plasma was reported.

Plasma Concentration Prior to the Next Dose (Ctrough) of MP1032

Ctrough of MP1032 in plasma was reported.

Average Observed Plasma Concentration at Steady State of MP1032

Average observed plasma concentration at steady state of MP1032 was reported.

Full Information

NCT ID

NCT04932941

First Posted

June 18, 2021

Last Updated

June 12, 2023

Sponsor

MetrioPharm AG

Collaborators

Syneos Health, LLC

1. Study Identification

Unique Protocol Identification Number

NCT04932941

Brief Title

MP1032 Treatment in Patients With Moderate to Severe COVID-19

Official Title

A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19

Study Type

Interventional

2. Study Status

Record Verification Date

June 2023

Overall Recruitment Status

Completed

Study Start Date

October 19, 2021 (Actual)

Primary Completion Date

July 28, 2022 (Actual)

Study Completion Date

September 5, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

MetrioPharm AG

Collaborators

Syneos Health, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Product Manufactured in and Exported from the U.S.

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

COVID-19

Keywords

COVID-19, MP1032

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

132 (Actual)

8. Arms, Groups, and Interventions

Arm Title

MP1032

Arm Type

Experimental

Arm Description

Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.

Intervention Type

Drug

Intervention Name(s)

MP1032

Intervention Description

Hard gelatin capsules for oral administration.

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Placebo capsules matched to MP1032 for oral administration.

Primary Outcome Measure Information:

Title

Percentage of Participants With Disease Progression Using National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale at Day 14

Description

Time Frame

At Day 14

Secondary Outcome Measure Information:

Title

Percentage of Participants With Disease Progression Using NIAID 8-point Ordinal Scale at Day 28

Description

Disease progression was defined as the percentage of participants who were not alive or who had respiratory failure. Respiratory failure was defined as participants who had a score of 2, 3 or 4 on the NIAID 8-point ordinal scale: The NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or ECMO; 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status.

Time Frame

At Day 28

Title

Percentage of Participants With Disease Resolution at Day 28

Description

Time Frame

At Day 28

Title

All-cause Mortality Rate up to Day 28

Description

All-cause mortality rate was the percentage of participants in each treatment group who died by Day 28 were reported.

Time Frame

Up to Day 28

Title

Change From Baseline in Clinical Status Score Related to COVID-19 According to the NIAID 8-point Ordinal Scale at Day 28

Description

Time Frame

Baseline, Day 28

Title

Percentage of Participants With Disease Resolution at Day 14

Description

Time Frame

At Day 14

Title

All-cause Mortality Rate up to Day 14 and Day 60

Description

The percentage of participants who died by Day 14 and Day 60 were reported.

Time Frame

Up to Day 14 and Day 60

Title

Change From Baseline in Clinical Status Score Related to COVID-19 According to the NIAID 8-point Ordinal Scale at Day 14

Description

Time Frame

Baseline, Day 14

Title

Percentage of Participants Who Required Invasive Ventilation (Mechanical Ventilator and/ ECMO), or Who Died at Day 14 and Day 28

Description

Percentage of participants who required invasive mechanical ventilation/ECMO or who died by Day 14 and Day 28 were reported.

Time Frame

At Day 14 and Day 28

Title

Change From Baseline in Clinical Status Score of the NIAID 8-point Ordinal Scale at Each Visit

Description

Time Frame

Baseline up to Day 60

Title

Time to (First) Improvement of at Least 1 Category on the NIAID 8-point Ordinal Scale

Description

The NIAID scale is an assessment of clinical status on a given study day and was defined as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or ECMO; 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Participants who did not improve at least 1 category on the NIAID scale or died before Day 28 were censored at Day 28. The total score range was 1 to 8 where, higher score indicates improvement in the clinical status.

Time Frame

Baseline up to Day 28

Title

Percentage of Participants With Clinical Status Improvement of at Least 1 Category From Baseline on the NIAID 8-point Ordinal Scale at Day 14 and Day 28

Description

Time Frame

Baseline, Day 14 and Day 28

Title

Time to Discharge by Day 28 and Day 60

Description

Time to discharge i.e., the total duration of participant hospitalization from baseline to discharge at Day 28 and Day 60 was reported.

Time Frame

Baseline, Day 28 and Day 60

Title

Percentage of Participants Who Were Alive and Tested Negative for COVID-19 at Day 14, Day 28, and Day 60

Description

Percentage of participants who were alive and tested negative for COVID-19 at Day 14, Day 28, and Day 60 were reported.

Time Frame

At Day 14, Day 28 and Day 60

Title

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

Description

Time Frame

Day 1 up to Day 60

Title

Number of Participants With Clinically Significant Change in Vital Sign

Description

Time Frame

Day 1 up to Day 60

Title

Number of Participants With Clinically Significant Abnormalities in Physical Examinations

Description

Time Frame

Baseline up to Day 60

Title

Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Results

Description

Time Frame

Baseline up to Day 60

Title

Maximum Observed Plasma Concentration (Cmax) of MP1032

Description

Cmax of MP1032 in plasma were reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.

Time Frame

Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7

Title

Area Under the Plasma Concentration-time Curve From Time Zero to Last Non-zero Concentration (AUC0-t) of MP1032

Description

AUC0-t of MP1032 in plasma were reported. Geometric mean and geometric coefficient of variation percent (CV%) was reported.

Time Frame

Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7

Title

Apparent Elimination Rate Constant (Kel) of MP1032

Description

Time Frame

Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1

Title

Apparent Body Clearance (CL/F) of MP1032

Description

Cl/F was estimated as Dose/AUC0-inf. CL/F of MP1032 in plasma was reported.

Time Frame

Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1

Title

Apparent Volume of Distribution (Vz/F) of MP1032

Description

Vz/F was estimated as Dose/(Kel x AUC0-inf). Vz/F of MP1032 in plasma was reported.

Time Frame

Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1

Title

Plasma Concentration Prior to the Next Dose (Ctrough) of MP1032

Description

Ctrough of MP1032 in plasma was reported.

Time Frame

Pre-dose concentration (Day 2, Day 7, and Day 8).

Title

Average Observed Plasma Concentration at Steady State of MP1032

Description

Average observed plasma concentration at steady state of MP1032 was reported.

Time Frame

Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Key Inclusion Criteria: Participant is admitted to hospital and has a positive severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) test by standard reverse transcription-polymerase chain reaction (RT-PCR) assay or equivalent test Participant has the presence of any symptom(s) suggestive of moderate or severe systemic illness with COVID-19 Key Exclusion Criteria: Participant, in opinion of the investigator, is not likely to survive >=48 hours beyond Day 1 Participant has a diagnosis of asymptomatic COVID-19, mild COVID-19, or critical COVID-19 on Day 1 Participant has a documented medical history of infection with hepatitis A, B, C, or with human immunodeficiency virus (with a detectable viral load and CD4 count <500 cells per micro liter), or a documented active infection with tuberculosis. The Participant has clinically significant electrocardiogram (ECG) abnormalities at screening Other protocol defined inclusion/exclusion criteria may apply

Facility Information:

Facility Name

Snake River Research PLLC

City

Idaho Falls

State/Province

Idaho

ZIP/Postal Code

83404

Country

United States

Facility Name

Richmond University Medical Center

City

Staten Island

State/Province

New York

ZIP/Postal Code

10310

Country

United States

Facility Name

MHAT Blagoevgrad AD

City

Blagoevgrad

Country

Bulgaria

Facility Name

MHAT Sv. Ivan Rilski Kozloduy

City

Kozloduy

Country

Bulgaria

Facility Name

MHAT Dr. Stamen Iliev AD

City

Montana

Country

Bulgaria

Facility Name

SHATPD Pernik EOOD

City

Pernik

Country

Bulgaria

Facility Name

MHAT Dr. Ivan Seliminski AD

City

Sliven

Country

Bulgaria

Facility Name

Umhatem"N.I.Pirogov"

City

Sofia

Country

Bulgaria

Facility Name

SHATPPD Sata Zagora EOOD

City

Stara Zagora

Country

Bulgaria

Facility Name

Centre Hospitalier Victor Dupouy

City

Argenteuil

Country

France

Facility Name

CHU de Grenoble Alpes

City

Grenoble Cedex 9

Country

France

Facility Name

Centre Hospitalier Lyon Sud

City

Pierre-Benite CEDEX

Country

France

Facility Name

DE KK Infektológiai Klinika

City

Debrecen

Country

Hungary

Facility Name

Flor Ferenc Hospital of Pest County

City

Kistarcsa

Country

Hungary

Facility Name

Ospedale GB Morgagni

City

Forlì

Country

Italy

Facility Name

Ospedale SM Goretti

City

Latina

Country

Italy

Facility Name

IRCCS Ospedale San Raffaele

City

Milano

Country

Italy

Facility Name

ASST-FBF-SACCO - Ospedale Luigi Sacco

City

Milan

Country

Italy

Facility Name

Policlinico di Napoli

City

Napoli

Country

Italy

Facility Name

Ospedale "Santo Spirito! Pescara

City

Pescara

Country

Italy

Facility Name

Policlinico Agostino Gemelli

City

Roma

Country

Italy

Facility Name

Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes"

City

Bucharest

Country

Romania

Facility Name

Spitalul Municipal Caracal

City

Caracal

Country

Romania

Facility Name

Spitalul Clinic de Boli Infectioase "Sfanta Parascheva"

City

Iaşi

Country

Romania

Facility Name

Clinica Anestezie si Terapie Intensiva

City

Timişoara

Country

Romania

Facility Name

Hospital Clinic de Barcelona Hospital Clinic i Provincial

City

Barcelona

Country

Spain

Facility Name

Hospital Ramon y Cajal, Edificio Central

City

Madrid

Country

Spain

Facility Name

Hospital Clínico Universitario de Salamanca

City

Salamanca

Country

Spain

Facility Name

Hospital Universitario Marqués de Valdecilla/IDIVAL

City

Santander

Country

Spain

Facility Name

Hospital Universitario de Valme

City

Sevilla

Country

Spain

Facility Name

Hospital Álvaro Cunqueiro

City

Vigo

Country

Spain

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

MP1032 Treatment in Patients With Moderate to Severe COVID-19

We'll reach out to this number within 24 hrs